Eli Lilly is partnering with Walmart to offer Zepbound through its direct-to-consumer program, making the popular medication ...

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and spawning a ...

Eli Lilly & Co. raised its full-year guidance as revenue from its blockbuster weight loss and diabetes drugs beat ...

Eli Lilly shares surged after strong third-quarter results and a raised annual forecast, powered by booming demand for its ...

The top China executive of US pharmaceutical company Eli Lilly and Co said on Wednesday that the company aims to make its ...

Eli Lilly has arguably taken the lead in the obesity drug space. Novo Nordisk has struggled, but remains a top contender with a potential catalyst looming. Viking Therapeutics is a riskier choice, but ...

"Massive sales for weight loss drugs spur Eli Lilly’s Q3" was originally created and published by Pharmaceutical Technology, ...

Mounjaro and Zepbound have helped boost the company's market cap. New data indicate these drugs do more than just help patients lose weight, contributing to potentially lowering risks to hearts and ...

Novo Nordisk has fallen behind its archrival, Eli Lilly, in the obesity drug market. Compounded GLP-1 drugs have become such an issue that Novo Nordisk changed its CEO. Expectations are so low that ...

Eli Lilly (NYSE: LLY) is the most valuable healthcare stock in the world, with a market capitalization of more than $760 billion. It has been soaring in recent years due to the success of its highly ...

It has a couple of GLP-1 products that account for more than half of its top line. Competition in this space has been on the rise, including from top pharma companies. Eli Lilly (NYSE: LLY) is the ...